Effects of a short course of eszopiclone on continuous positive airway pressure adherence: A randomized trial

Walter Reed Army Medical Center, Washington, DC 20307, USA.
Annals of internal medicine (Impact Factor: 17.81). 11/2009; 151(10):696-702. DOI: 10.1059/0003-4819-151-10-200911170-00006
Source: PubMed


Adherence to short-term continuous positive airway pressure (CPAP) may predict long-term use. Unfortunately, initial CPAP intolerance may lead to poor adherence or abandonment of therapy.
To determine whether a short course of eszopiclone at the onset of therapy improves long-term CPAP adherence more than placebo in adults with obstructive sleep apnea.
Parallel randomized, placebo-controlled trial from March 2007 to December 2008. Randomization, maintained and concealed centrally by pharmacy personnel, was computer-generated using fixed blocks of 10. Referring physicians, investigators, and patients were blinded to the treatment assignment until after the final data were collected. ( registration number: NCT00612157).
Academic sleep disorder center.
160 adults (mean age, 45.7 years [SD, 7.3]; mean apnea-hypopnea index, 36.9 events/h [SD, 23]) with newly diagnosed obstructive sleep apnea initiating CPAP. Intervention: Eszopiclone, 3 mg (n = 76), or matching placebo (n = 78) for the first 14 nights of CPAP.
Use of CPAP was measured weekly for 24 weeks. Adherence to CPAP (primary outcome) and the rate of CPAP discontinuation and improvements in symptoms (secondary outcomes) were compared. Follow-up at 1, 3, and 6 months was completed by 150, 136, and 120 patients, respectively. Results: Patients in the eszopiclone group used CPAP for 20.8% more nights (95% CI, 7.2% to 34.4%; P = 0.003), 1.3 more hours per night for all nights (CI, 0.4 to 2.2 hours; P = 0.005), and 1.1 more hours per night of CPAP use (CI, 0.2 to 2.1 hours; P = 0.019). The hazard ratio for discontinuation of CPAP was 1.90 (CI, 1.1 to 3.4; P = 0.033) times higher in the placebo group. Side effects were reported in 7.1% of patients and did not differ between groups.
Patients had severe obstructive sleep apnea treated at a specialized sleep center with frequent follow-up; results may not be generalizable to different settings. Patients' tolerance to CPAP and their reasons for discontinuation were not assessed.
Compared with placebo, a short course of eszopiclone during the first 2 weeks of CPAP improved adherence and led to fewer patients discontinuing therapy.

Download full-text


Available from: Christopher Lettieri, Jan 07, 2014
1 Follower
21 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Integration of magnetic elements is one of the most important aims in the electronics industry, since it allows a reduction in the size of power electronics equipment. This paper presents a method to design integrated magnetic elements using thick-film technology. A DC-to-DC power converter has been built and tested to validate this technology. Experimental results obtained and conclusions derived are also presented
    Applied Power Electronics Conference and Exposition, 1998. APEC '98. Conference Proceedings 1998., Thirteenth Annual; 03/1998
  • [Show abstract] [Hide abstract]
    ABSTRACT: The constellation of conditions associated with sleep-disordered breathing (SDB) has emerged as a highly prevalent multifactorial array of conditions that are, in turn, associated with multisystem disorder involvement. In the last 5 years alone, more than 7,000 scholarly articles have been published in the biomedical literature, and have expanded our understanding of the mechanisms leading to SDB as well as those underlying the extensive list of morbid consequences. As in previous years (1, 2), the American Journal of Respiratory and Critical Care Medicine has continued in 2009 with its tradition of publishing innovative and high-impact papers on these topics.
    American Journal of Respiratory and Critical Care Medicine 03/2010; 181(6):545-9. DOI:10.1164/rccm.200912-1948UP · 13.00 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To review studies examining the cooccurrence of insomnia and obstructive sleep apnea (OSA), explore evidence for the effect of OSA therapy on insomnia symptoms and the effect of insomnia treatments on breathing and sleep in patients with OSA, and discuss challenges in the evaluation and treatment of comorbid insomnia and OSA. Seven pertinent studies were identified that assessed the prevalence of comorbid insomnia and OSA or sleep disordered breathing. Four studies were identified that examined the effects of OSA treatment in patients with insomnia, and 8 studies were found that examined hypnotic use in patients with OSA or sleep disordered breathing. A high prevalence (39%-58%) of insomnia symptoms have been reported in patients with OSA, and between 29% and 67% of patients with insomnia have an apnea-hypopnea index of greater than 5. Combination therapy, including both cognitive behavior therapy and OSAtreatment, resulted in greater improvements in insomnia than did either cognitive behavior therapy or OSA treatment alone. The use of GABAergic nonbenzodiazepine agents has been associated with improvements in sleep and has little to no effect on the apnea-hypopnea index in patients with OSA. Insomnia and OSA frequently cooccur. The optimal strategy for adequately treating comorbid insomnia and OSA remains unclear. Future research examining the impact of insomnia on continuous positive airway pressure therapy is needed. Given the substantial overlap in symptoms between insomnia and OSA, evaluation and treatment of these 2 conditions can be challenging and will require multidisciplinary collaboration among sleep specialists.
    Journal of clinical sleep medicine: JCSM: official publication of the American Academy of Sleep Medicine 04/2010; 6(2):196-204. · 3.05 Impact Factor
Show more